Title & Introduction

  • Paper Title: Into the Wild Frontier: Mapping the Terrain of Adverse Events in Psychedelic-Assisted Therapies
  • Published In: Journal of Psychopharmacology, 2024
  • Authors: Otto Simonsson, Simon B. Goldberg, Peter S. Hendricks
  • Objective/Research Question: This study aims to explore the risks associated with psychedelic-assisted therapies (PATs) by evaluating potential adverse events (AEs) to develop a comprehensive and standardized assessment framework.
  • Importance: Understanding and mitigating risks is essential for the approval and safe implementation of PATs in clinical settings, given their potential for treating psychiatric disorders such as treatment-resistant depression, PTSD, and generalized anxiety.

Summary & Takeaways

Key Takeaway: A standardized framework for assessing AEs in PATs is essential for advancing the safety and efficacy of these therapies in treating psychiatric disorders.

Practical Application: This framework provides a foundation for future trials and clinical guidelines, balancing thorough AE assessments with practicality.

Key Background Information

  • Context: Psychedelic-assisted therapies have shown promise for psychiatric conditions, earning FDA breakthrough designations for substances like psilocybin, MDMA, and LSD. However, distinct risks tied to the unique spiritual and psychological effects of psychedelics remain underexplored.
  • Hypothesis: Psychedelics' interaction with psychotherapy introduces unique AEs that require specific assessment beyond traditional frameworks for pharmacotherapy and psychotherapy.

Methodology

  • Study Design: This study reviews existing frameworks and literature on PATs and adverse events, proposing a new assessment approach.
  • Framework Overview: The authors identify 54 potential AEs associated with PATs, incorporating insights from existing pharmacotherapy, psychotherapy, and nascent psychedelic research.
  • Scope: Includes risks unique to psychedelics, such as heightened suggestibility, and proposes tailored strategies to minimize biases like nocebo effects.

Key Findings

Primary Outcomes:

  • Developed a comprehensive framework to identify and assess 54 potential AEs in PATs.
  • Identified limitations in prior inconsistent and nonspecific AE reporting.
  • Proposed methods to balance AE assessments, including clinician- and informant-based evaluations.

Secondary Outcomes:

  • Emphasized risks such as nocebo effects exacerbated by psychedelic suggestibility.
  • Advocated for empirical validation and modifications of the framework to ensure feasibility.

Interpretation & Implications

  • Conclusion: The framework marks a critical step towards systematically evaluating AEs in PATs, contributing to the broader understanding and safety of psychedelic therapies.
  • Implications: Enhanced AE reporting could support safer clinical trials, improve patient outcomes, and address regulatory safety concerns.
  • Limitations: The framework may present a burden in pragmatic trials due to its comprehensiveness. Future validation and a focus on clinically relevant AEs are necessary to refine the approach.

Researchers & Publication

Share this post